| Name | Title | Contact Details |
|---|
ZEA manufactures plant biologics for pharmaceutical uses providing wellness to the world. At ZEA, we are uprooting medicine by growing plants and using our proprietary technology to produce medicinal plant products and we offer superior data analytics in what is a $400 billion dollar market.
Redbridge is an insurance and reinsurance management group that specializes in global operations. The company offers a comprehensive range of services across various sectors, including life, health, personal accident, and property & casualty insurance. Redbridge serves both individual and corporate clients through its specialized divisions and subsidiaries. The company underwrites a variety of insurance products, including individual and group life and health policies, as well as general insurance. Its reinsurance offerings cover areas such as property, construction, professional risk, and marine. Additionally, Redbridge provides assistance services through Redbridge Assist, which includes travel, medical, and home assistance plans. The company also operates an insurance brokerage that focuses on sales and marketing for various insurance products. Redbridge is dedicated to delivering high-quality services, including medical case management and claims handling, supported by a 24/7 international operating center. The company caters to a diverse clientele, including insurance companies and corporate clients, with a strong presence in emerging insurance markets worldwide.
FifthWall Solutions is a top-rated cyber insurance partner that works with 1,500+ MSPs and their clients, accessing 45+ carriers to offer the best rates and coverage options. FifthWall also educates and equips MSPs to navigate the cyber insurance process for their clients and leverage their stack along the way. Interested in partnering with FifthWall Solutions? Message us at info@fifthwallsolutions.com or call us at 844.719.0981.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.